Please use this identifier to cite or link to this item: http://ricaxcan.uaz.edu.mx/jspui/handle/20.500.11845/1476
Full metadata record
DC FieldValueLanguage
dc.contributor49237es_ES
dc.coverage.spatialGlobales_ES
dc.creatorDelgado Enciso, Iván-
dc.creatorPaz García, Juan-
dc.creatorRodríguez Hernández, Alejandrina-
dc.creatorMadrigal Pérez, Violeta-
dc.creatorCabrera Licona, Ariana-
dc.creatorGarcía Rivera, Alejandro-
dc.creatorSoriano Hernandez, Alejandro-
dc.creatorCortés Bazan, José-
dc.creatorGalván Salazar, Héctor-
dc.creatorValtierra Álvarez, José-
dc.creatorGuzmán Esquivel, José-
dc.creatorRodríguez Sánchez, Iram Pablo-
dc.creatorMartínez Fierro, Margarita de la Luz-
dc.creatorPaz Michel, Brenda-
dc.date.accessioned2020-03-31T20:47:54Z-
dc.date.available2020-03-31T20:47:54Z-
dc.date.issued2018-03-
dc.identifierinfo:eu-repo/semantics/publishedVersiones_ES
dc.identifier.issn1791-2997es_ES
dc.identifier.issn1791-3004es_ES
dc.identifier.urihttp://ricaxcan.uaz.edu.mx/jspui/handle/20.500.11845/1476-
dc.description.abstractOsteoarthritis (OA) is a chronic disorder of synovial joints, in which there is progressive softening and disintegration of the articular cartilage. OA is the most common form of arthritis, and is the primary cause of disability and impaired quality of life in the elderly. Despite considerable medical necessity, no treatment has yet been proven to act as a disease‑modifying agent that may halt or reverse the structural progression of OA. The replacement of the joint with a prosthesis appears to be the best option in the advanced stages of the disease. A formulation (BIOF2) for cartilage regeneration has been recently developed. The present study evaluated the effects of BIOF2 on gene expression in human cell cultures, followed by efficacy trials in three OA animal models. Human synovial fluid cells that were exposed to the formulation exhibited increased transcription factor SOX‑9 (SOX9; chondrogenic factor) expression, and decreased mimecan (mineralization inducer) and macrophage‑stimulating protein receptor (osteoclastogenic factor) expression. The intra‑articular application of BIOF2 in the animal models significantly increased cartilage thickness from 12 to 31% at 28 days, compared with articular cartilage treated with saline solution. The articular area and number of chondrocytes additionally increased significantly, maintaining an unaltered chondrocyte/mm2 proportion. Evaluation of the histological architecture additionally displayed a decrease in the grade of articular damage in the groups treated with BIOF2. In conclusion, BIOF2 has proven to be effective for treating OA in animal models, most likely due to SOX9 overexpression in articular cells.es_ES
dc.language.isoenges_ES
dc.publisherSpandidos publicationses_ES
dc.relationhttps://www.ncbi.nlm.nih.gov/pubmed/29286152es_ES
dc.relation.urigeneralPublices_ES
dc.rightsAtribución-NoComercial-CompartirIgual 3.0 Estados Unidos de América*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/us/*
dc.sourceMolecular Medicine Reports, Vol. 17, No. 3, marzo de 2018, pp. 3503-3510es_ES
dc.subject.classificationMEDICINA Y CIENCIAS DE LA SALUD [3]es_ES
dc.subject.otherOsteoarthritis (OA)es_ES
dc.subject.othereffects of BIOF2es_ES
dc.subject.otherSOX9; chondrogenic factores_ES
dc.titleA promising novel formulation for articular cartilage regeneration: Preclinical evaluation of a treatment that produces SOX9 overexpression in human synovial fluid cellses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
Appears in Collections:*Documentos Académicos*-- Doc. en Ing. y Tec. Aplicada

Files in This Item:
File Description SizeFormat 
mmr_17_3_3503_PDF.pdf995,09 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons